Back to Search
Start Over
Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience.
- Source :
- Scientific Reports; 7/4/2023, Vol. 13 Issue 1, p1-10, 10p
- Publication Year :
- 2023
-
Abstract
- Patients with acute myeloid leukemia (AML) and nucleophosmin 1 gene mutations (NPM1<superscript>mut</superscript>) show a favorable prognosis with chemotherapy (CT) in the absence of negative prognostic genetic abnormalities. Between 2008 and 2021 64 patients with NPM1<superscript>mut</superscript>AML received alloHSCT because of additional adverse prognostic factors (1st line), inadequate response to or relapse during or after CT (2nd line). To expand the evidence in alloTX in NPM1<superscript>mut</superscript> AML, clinical and molecular data were retrospectively analyzed with respect to pre-transplant strategies and outcome. Patients with minimal residual disease negative (MRD−) CR at transplant had better 2-y-PFS and 2-y-OS (77% and 88%) than patients with minimal residual disease positive (MRD+) CR (41% and 71%) or patients with active disease (AD) at transplant (20% and 52%). The 2nd line patients with relapse after completing CT responded well to high dose cytarabine based salvage chemotherapy (salvage CT) in contrast to patients relapsing while still on CT (90% vs 20%, P = 0.0170). 2-y-PFS and 2-y-OS was 86% in patients who achieved a 2nd MRD− CR pre alloHSCT. Outcome in NPM1<superscript>mut</superscript>AML depends on disease burden at alloHSCT. Time and type of relapse in relation to CT are predictive for response to salvage CT. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20452322
- Volume :
- 13
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Scientific Reports
- Publication Type :
- Academic Journal
- Accession number :
- 164707493
- Full Text :
- https://doi.org/10.1038/s41598-023-38037-5